Lyterian Therapeutics

What Lyterian Therapeutics does

Lyterian Therapeutics is a privately held, clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2022. The company is developing new medicines by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated disease targets. Its name is derived from the Greek λυτήριος (lutḗrios), meaning termination or healing, and the company's research philosophy is grounded in learning from the endogenous and exogenous agents that orchestrate tissue repair in nature. Lyterian serves patients with unmet medical needs rather than selling any commercial product today.

The company's scientific platform is anchored by five scientific founders drawn from leading academic and industry institutions: Aaron Gitler (Stanford), Micha Rapé (UC Berkeley / HHMI), Robert Tjian, Marius Wernig (Stanford), and Ingrid Wertz (formerly of Genentech and BMS). Operating leadership is provided by CEO Carly Weddle, Chief Business Officer Julie Kim, and SVP of Drug Discovery Zhonghua Pei. The in-house team of roughly 25 staff is organized across Biology, Biophysics, Protein Sciences, and Cellular and Assay Engineering, with a Chief of Staff function overseeing program management. The company has run a 2024 summer internship cohort and maintains active recruiting through Lever, indicating a deliberate multi-program discovery buildout. The recruiting email domain references The Column Group, suggesting an institutional venture capital backer.

Lyterian is pre-commercial: it has no marketed products, no disclosed revenue, no publicly named development candidates, and no announced partnerships in the input data. Its go-to-market path, typical for a discovery-stage biotech, would involve advancing assets toward investigational new drug (IND) enabling studies, pursuing pharma partnerships or collaborations, and ultimately seeking FDA approval for clinical trials and eventual commercialization. The company's economic model is therefore driven by external financing (venture capital, potential strategic upfronts, and future milestones) rather than product revenue.

Name

Lyterian Therapeutics

Legal name

Lyterian Therapeutics

Website

https://lyterian.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Lyterian Therapeutics is a preclinical-stage biopharmaceutical company developing medicines by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated disease targets for patients with unmet medical needs.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Protein homeostasis therapeutics
• Targeted protein degradation
• Drug discovery research
• Biopharmaceutical development
• Clinical-stage biotechnology

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Marketing channels1 record

Core offering

Lyterian Therapeutics is a clinical-stage biopharmaceutical company developing transformative medicines by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically-validated targets for treating disease. The company is in the drug discovery and development phase, with no commercialized pharmaceutical products currently marketed, and focuses on disease resolution coordinated by endogenous and exogenous agents that recruit cells and effectors to sites of injury.

Product overview

Lyterian Therapeutics is a biotechnology company developing transformative medicines by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically-validated targets for treating disease. The company is in the drug discovery and development phase with no commercialized pharmaceutical products currently marketed. The company's therapeutic approach focuses on disease resolution coordinated by endogenous and exogenous agents that recruit cells and effectors to sites of injury, incorporating learnings from nature's innate healing processes into medicine design.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights3 records

Direct peers

• Kymera Therapeutics: Clinical-stage biotech developing heterobifunctional degraders that co-opt the ubiquitin-proteasome system — closely comparable mechanism and genetically-validated target strategy to Lyterian.
• C4 Therapeutics: Developer of small-molecule degraders (Degronimids) that hijack protein homeostasis machinery, sharing Lyterian's platform-based, mechanism-driven discovery model.
• Monte Rosa Therapeutics: Focused on molecular glue degraders that redirect protein homeostasis pathways to disease targets — a direct mechanistic analogue and a useful comparator for Lyterian's value-creation trajectory.
• Arvinas: Pioneer in targeted protein degradation (PROTACs) — operates a protein-homeostasis-based discovery platform targeting genetically validated disease drivers, directly analogous to Lyterian's stated approach.

Emerging players

• Foghorn Therapeutics: Discovery-stage biotech targeting chromatin regulatory biology using genetically validated targets — overlaps with Lyterian on the 'genetically validated targets' discovery philosophy even though the modality differs.
• Neomorph: Founded by protein-degradation scientific leaders (including Benjamin Ebert) to pursue molecular glue degraders — comparable stage, mechanism, and academic-founding profile to Lyterian.
• Plexium: Discovery-stage platform company focused on targeted protein degradation and E3 ligase expansion — comparable stage and target-class focus to Lyterian.
• BioTheryX: Developer of protein degraders and modulators of protein homeostasis, sharing Lyterian's focus on leveraging endogenous degradation pathways for therapeutic effect.
• Amphista Therapeutics: Develops targeted protein degraders with novel mechanisms beyond cereblon/VHL E3 ligases, broadening the protein-homeostasis toolkit Lyterian also relies on.
• Lycia Therapeutics: Discovery-stage company developing lysosomal-targeting chimeras (LYTACs) that exploit extracellular protein homeostasis — adjacent mechanism in the broader protein-homeostasis drug-development space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyterian Therapeutics